Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 40
Summary
- Conditions
- Colorectal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Stage IV Colorectal Cancer AJCC v7
- Stage IV Pancreatic Cancer AJCC v6 and v7
- Stage IVA Colorectal Cancer AJCC v7
- Stage IVB Colorectal Cancer AJCC v7
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. Demonstrate that developing a custom vaccine for metastatic pancreatic ductal adenocarcinoma (PDA) and colorectal cancer (CRC) patients is feasible. II. Show that a custom peptide-based vaccine in combination with pembrolizumab is safe. SECONDARY OBJECTIVES: I. Determine preli...
PRIMARY OBJECTIVES: I. Demonstrate that developing a custom vaccine for metastatic pancreatic ductal adenocarcinoma (PDA) and colorectal cancer (CRC) patients is feasible. II. Show that a custom peptide-based vaccine in combination with pembrolizumab is safe. SECONDARY OBJECTIVES: I. Determine preliminary clinical efficacy. II. Demonstrate the antigenicity of each vaccine. OUTLINE: Patients receive personalized synthetic tumor-associated peptide vaccine therapy subcutaneously (SC) on day 1 of weeks 0, 1, 3, 4 and 6, then every 3 weeks until week 30, then at weeks 39 and 51. Beginning 30 minutes after each vaccine is administered, patients then receive imiquimod cream topically after 30 minutes. Patients also receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Courses with pembrolizumab repeat every 3 weeks until week 51 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up 2 times in 6 months.
Tracking Information
- NCT #
- NCT02600949
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Michael J Overman M.D. Anderson Cancer Center